Triazole antifungal
Isavuconazole
Brand names: Cresemba
Adult dose
Dose: Loading 200mg every 8h for 6 doses, then 200mg OD; PO/IV bioequivalent
Route: PO/IV
Frequency: OD (after loading)
Clinical pearls
- Invasive aspergillosis and mucormycosis
- Unlike other azoles — does NOT prolong QT (and may shorten)
Contraindications
- Concurrent strong CYP3A4 inducers
- Familial short QT syndrome
- Hypersensitivity
Side effects
- Hepatotoxicity
- GI upset
- QT shortening (unique among azoles)
- Hypokalaemia
- Headache
- Infusion reactions
Interactions
- Strong CYP3A4 modulators
- Tacrolimus/ciclosporin (raised levels)
- Warfarin
Monitoring
- LFTs
- Drug levels (selected cases)
- Trough levels of co-prescribed CYP3A4 substrates
Reference: BNF; NICE TA487/TA738; SmPC; https://bnf.nice.org.uk/drugs/isavuconazole/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023